Arcline to Sell Medical Manufacturing Technologies to Perimeter Solutions for $685 Million

Rhea-AI Summary

Arcline announced a definitive agreement to sell portfolio company Medical Manufacturing Technologies (MMT) to Perimeter Solutions (NYSE: PRM) for $685 million. MMT is a Charlotte-based provider of automated medical device manufacturing with >350 employees, 14 production facilities, and service to more than 1,000 customers, including OEMs and CDMOs that make catheters, guidewires, stents, and related components.

The transaction follows Arcline's 2020 acquisition and 13 add-on deals that the firm says materially grew MMT's revenue and EBITDA. Closing is expected in Q1 2026, subject to regulatory approvals and customary closing conditions.

Positive

• $685 million definitive sale price to Perimeter
• MMT operates 14 production facilities
• MMT serves more than 1,000 customers globally
• Transaction expected to close in Q1 2026

Negative

• Closing is subject to regulatory approvals and customary conditions

Key Figures

MMT purchase price $685 million Cash consideration for acquisition by Perimeter Solutions

Customer count More than 1,000 customers Global medical device manufacturing customers served by MMT

Employee count Over 350 employees MMT workforce size

Production facilities 14 facilities MMT global production footprint

Acquisitions completed 13 acquisitions Targeted deals completed by Arcline to expand MMT

Acquisition timing First quarter of 2026 Expected closing period for MMT transaction

Initial MMT acquisition year 2020 Year Arcline first acquired MMT

Market Reality Check

$28.71 Last Close

Volume Volume 1,394,875 shares is 1.48x the 20-day average of 944,581 shares. normal

Technical Price $28.71 is trading above the 200-day MA of $16.91 and within 2.05% of the 52-week high.

Peers on Argus

PRM showed a modest -0.66% move while key specialty chemicals peers like AVNT, FUL, HWKN, KWR, and WDFC were all positive between 0.92% and 5.21%, indicating stock-specific dynamics rather than a sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Jul 28	Earnings call timing	Neutral	-1.4%	Announcement of date and time for Q2 2025 earnings release and call.

Pattern Detected

Only one recent news-linked price reaction is available, showing a mild negative move on neutral scheduling news; no reliable reaction pattern can be inferred.

Recent Company History

Recent disclosures for Perimeter Solutions (PRM) show a mix of operational and corporate developments. A Q3 2025 10‑Q reported higher net sales of $315.4 million but a wider net loss of $90.7 million, largely due to $247.7 million in founders advisory fees, while operating cash flow lifted cash to $340.6 million. Capital allocation included two small acquisitions totaling $22.0 million and a re‑established $100.0 million buyback. Multiple Form 144 filings detailed sizable insider-related share sale plans. Against this backdrop, the new $685 million MMT acquisition continues an acquisitive strategy.

Market Pulse Summary

This announcement details PRM’s agreement to acquire MMT for $685 million in cash, extending its acquisitive track record. MMT brings more than 1,000 customers, over 350 employees, and 14 facilities focused on complex medical device manufacturing. Recent SEC filings showed PRM balancing growth investments and buybacks while managing a $90.7 million quarterly net loss driven by non‑operational fees. Investors may watch regulatory approvals, closing progress into Q1 2026, and updated financing and leverage metrics following completion.

Key Terms

ebitda financial

"The firm significantly grew the company's revenue and EBITDA and completed 13 targeted acquisitions"

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It measures a company's profitability by focusing on the money it makes from its core operations, ignoring expenses like taxes and accounting adjustments. Investors use EBITDA to compare how well different companies are performing financially, as it provides a clearer picture of operational success without the influence of financial structure or accounting choices.

oems technical

"including many of the world's leading medical technology OEMs and CDMOs"

OEMs, or Original Equipment Manufacturers, are companies that produce the main components or products that other companies use to build finished goods. For investors, OEMs are important because their performance can influence the supply chain, manufacturing costs, and overall market trends in industries like technology, automotive, and electronics. Their success often reflects broader economic health and consumer demand.

AI-generated analysis. Not financial advice.

NASHVILLE, Tenn., Dec. 11, 2025 /PRNewswire/ -- Arcline Investment Management ("Arcline"), a growth-oriented private equity firm, today announced it has entered into a definitive agreement to sell its portfolio company Medical Manufacturing Technologies ("MMT"), to Perimeter Solutions, Inc (NYSE: PRM) ("Perimeter") for $685 million.

Based in Charlotte, North Carolina, MMT is a leading global provider of medical device manufacturing solutions, serving as a single-resource partner for automated, process-driven medical manufacturing. The company supports more than 1,000 customers — including many of the world's leading medical technology OEMs and CDMOs — in the production of complex interventional medical devices such as catheters, guidewires, stents, microcoils, and related components. With over 350 employees and 14 production facilities, MMT is a critical partner to customers operating in precision-dependent and highly regulated environments.

Since acquiring MMT in 2020, Arcline has executed a disciplined strategy to build a scaled provider of mission-critical manufacturing technologies for medical device OEMs and CDMOs. The firm significantly grew the company's revenue and EBITDA and completed 13 targeted acquisitions that broadened MMT's capabilities, including automation solutions and specialty manufacturing services that simplify and optimize complex production processes. Arcline thanks Chief Executive Officer Robbie Atkinson and the entire MMT team for their partnership. 

The transaction is expected to close in the first quarter of 2026, subject to regulatory approvals and customary closing conditions.

William Blair and Houlihan Lokey served as financial advisors, and Kirkland & Ellis LLP and Fredrikson & Byron P.A. served as legal advisors to Arcline in connection with the transaction.

About Arcline Investment Management
Arcline Investment Management is a growth-oriented private equity firm with over $20 billion in assets under management. Arcline seeks to build the next generation of Industrial Compounders – market-leading, non-disruptible industrial platforms designed to consistently grow earnings over decades. For more information visit www.arcline.com.

Contact Information:
contact@arcline.com
www.arcline.com

Contact (For Press Inquiries Only):

Tim Ragones / Alexander Wolfson
Joele Frank, Wilkinson Brimmer Katcher
Arcline-JF@joelefrank.com
(212) 355-4449

View original content:https://www.prnewswire.com/news-releases/arcline-to-sell-medical-manufacturing-technologies-to-perimeter-solutions-for-685-million-302638695.html

SOURCE Arcline Investment Management

FAQ

How much is Perimeter Solutions paying for MMT (PRM transaction)?

Perimeter Solutions agreed to buy MMT for $685 million under a definitive agreement.

When is the Perimeter (PRM) acquisition of MMT expected to close?

The transaction is expected to close in Q1 2026, subject to regulatory approvals and customary closing conditions.

What does MMT bring to Perimeter (PRM) in terms of scale and customers?

MMT has >350 employees, 14 production facilities, and serves more than 1,000 customers, including medical device OEMs and CDMOs.

Did Arcline grow MMT before the sale to Perimeter (PRM)?

Arcline acquired MMT in 2020 and completed 13 targeted acquisitions, reporting growth in the company's revenue and EBITDA.

Are there regulatory hurdles for Perimeter's (PRM) purchase of MMT?

Yes. The deal closing is explicitly subject to regulatory approvals and customary closing conditions.